



FOR IMMEDIATE RELEASE

Althea granted Licence to Export

- Althea granted Licence to Export medicinal cannabis
- Althea supply to domestic patients continues to grow, with 156 patients and 54 prescribers in its network
- Planning permit lodged for ODC approved production facility

Melbourne, Australia, 13 November 2018: Althea Group Holdings Limited (**ASX:AGH**) today announces that its wholly owned subsidiary Althea Company Pty Ltd has been granted a Licence to Export by the Australian Government's Office of Drug Control (**ODC**).

The licence provides Althea with authorisation to export medicinal cannabis products and/or cannabis extracts, manufactured in Australia, under its recently issued Manufacture Licence (in accordance with relevant export permits).

"The licence to export brings us yet another step closer to becoming a global medicinal cannabis producer," said Althea CEO Josh Fegan. "Whilst we have only been listed publicly for seven weeks, the recent granting of key licences from the Office of Drug Control is a culmination of nearly two years of hard work." Althea now has a full set of production licences including cultivation, manufacture and export; to complement its earlier licence to import.

"We are now seeing strong growth and rapid advancements in many areas of the business, with October being our biggest month to date. I am proud to say there are now 156 patients in Australia being treated with Althea medicinal cannabis, prescribed by some 54 GPs and specialists." Mr Fegan added.

"The TGA received 329 SAS B applications in October, which is the highest number I've seen to date; although we credit the increase of Althea patients to our *Althea Concierge* medical education program," said Mr Fegan. "Concierge launched in late September and already 285 patients and 93 doctors have registered to the platform. Doctors are choosing *Althea Concierge* to educate themselves about medicinal cannabis and to initiate TGA applications, especially once they witness their peers achieving great outcomes."

Althea has a full complement of ODC cannabis licences and a growing patient base, as it looks to build out its Melbourne-based production facility in 2019. A planning permit for Althea's ODC approved fully-scalable 4,080m² medicinal cannabis cultivation, extraction and manufacturing facility, was lodged on November 12th, 2018. "Progress of the Melbourne facility is well and truly on track, having received great support from council and the Victorian Government," said Mr Fegan. "The project is looking good to be completed on time, towards the end of 2019."

For more information about Althea visit www.althea.com.au



-ENDS-

About Althea

Althea was founded in Melbourne in 2017 with a view to acquiring the necessary licences and permits to import, cultivate, produce and supply medicinal cannabis for eligible patients across Australia. Through strategic supply and distribution partnerships, Althea has been able to commence sales of five Althea branded medicinal cannabis products in Australia.

Althea's focus on patient care underpins its business strategy and its innovative web-based platform and mobile application, known as Althea Concierge, is designed to educate and support patient access to medicinal cannabis in Australia. Althea has also engaged a team of medical science liaisons to assist medical practitioners to become prescribers, and pharmacists to become suppliers, of Althea products.

Althea:

Josh Fegan, CEO & Managing Director

1300 70 20 20 | contact@althea.com.au

Investors:

PAC Partners Securities

03 8633 9834 | enquiries@pacpartners.com.au

Media contacts:

Sophie Mayes, Keep Left on behalf of Althea

03 9268 7800 | sophie@keepleft.com.au